The collaboration will develop sequencing technologies and advance precision medicine.
Biotechnology companies Illumina and Tempus AI are combining technologies to accelerate clinical adoption of molecular testing for patients.
"By expanding our collaboration with Illumina, we are combining our strengths in technology and data analytics with their strengths in developing new sequencing technologies to drive forward innovation and advance precision medicine," said Tempus chief commercial officer Terron Bruner.
Frequently, precision medicine is not used because molecular profiling is not yet standard across disease areas and regions.
Tempus, which uses AI to advance precision medicine and care, will use its multimodal data platform to train genomic algorithms. The collaboration will use Tempus’ multimodal data to improve Illumina’s AI molecular analysis technologies and support the clinical value of sequencing.
Findings from this collaboration will be used to build evidence packages required to standardise comprehensive genetic profiling and other molecular testing across major disease areas.
"In the era of true precision medicine, every patient who is battling complex disease should be routed to the optimal therapy based on molecular insights," said Illumina chief commercial officer Everett Cunningham.
"We envision a world where the full range of molecular profiling is available as part of the standard of care—not just in cancer, but in cardiology, neurology, immunology, and every other category of disease."
Earlier this month, Illumina and NashBio sequenced a total of 250,000 whole genomes for the Alliance for Genomic Discovery (AGD) initiative.
